{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"95"}]}],"title":"Clinical Benefit Response (sCR+CR+VGPR+PR+MR)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}],"title":"Complete Response"},{"categories":[{"measurements":[{"groupId":"OG000","value":"13"}]}],"title":"Very Good Partial Response"},{"categories":[{"measurements":[{"groupId":"OG000","value":"47"}]}],"title":"Partial Response"},{"categories":[{"measurements":[{"groupId":"OG000","value":"34"}]}],"title":"Minimal Response"}],"denoms":[{"counts":[{"groupId":"OG000","value":"257"}],"units":"Participants"}],"description":"sCR, CR, VGPR, PR, and minimal response (MR)","groups":[{"description":"In Cycle 1, subjects will receive carfilzomib 20 mg/m2 intravenously on Days 1, 2, 8, 9, 15, and 16. If all doses are administered and well-tolerated over the 28-day cycle, beginning with Cycle 2 the dose will escalate to 27 mg/m2 intravenously on Days 1, 2, 8, 9, 15, and 16 for all subsequent cycles.\n\nAssessed by Independent Review Committee","id":"OG000","title":"Carfilzomib (A1)"}],"paramType":"NUMBER","populationDescription":"Response-Evaluable Population:\n\n1. had measurable disease at Baseline\n2. received at least 1 dose of carfilzomib\n3. underwent baseline disease response assessments and at least 1 post-baseline disease assessment, or discontinued protocol treatment before Cycle 2 Day 1 due to an AE that was considered to be possibly or probably related to carfilzomib","reportingStatus":"POSTED","timeFrame":"Response assessments same as described in primary outcome measure","title":"Clinical Benefit Response (CBR) (A1 Only)","type":"SECONDARY","unitOfMeasure":"participants"}